Autolus Therapeutics plc (AUTL)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
AUTL price, last 12 months
Key stats
- Previous close
- $1.06
- Open
- $1.08
- Day range
- $0.9700 – $1.08
- 52-week range
- $0.8963 – $2.58
- Volume
- 5.2M
- Avg volume (20 days)
- 2.9M
- Market cap
- $311.4M
Performance
Technicals and fundamentals
About Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $311.4M